Mutual of America Capital Management LLC Sells 872 Shares of Haemonetics Corporation $HAE

Mutual of America Capital Management LLC lessened its position in shares of Haemonetics Corporation (NYSE:HAE) by 3.4% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 24,983 shares of the medical instruments supplier’s stock after selling 872 shares during the period. Mutual of America Capital Management LLC owned approximately 0.05% of Haemonetics worth $1,864,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in HAE. Schwartz Investment Counsel Inc. boosted its holdings in shares of Haemonetics by 148.0% during the first quarter. Schwartz Investment Counsel Inc. now owns 374,500 shares of the medical instruments supplier’s stock worth $23,799,000 after acquiring an additional 223,500 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in shares of Haemonetics by 20.6% in the first quarter. Allspring Global Investments Holdings LLC now owns 966,167 shares of the medical instruments supplier’s stock valued at $60,888,000 after buying an additional 165,118 shares during the period. CWC Advisors LLC. boosted its stake in shares of Haemonetics by 33.6% in the first quarter. CWC Advisors LLC. now owns 4,118 shares of the medical instruments supplier’s stock valued at $262,000 after buying an additional 1,035 shares during the period. KBC Group NV boosted its stake in shares of Haemonetics by 19.9% in the first quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier’s stock valued at $154,000 after buying an additional 401 shares during the period. Finally, Skylands Capital LLC boosted its stake in shares of Haemonetics by 105.2% in the first quarter. Skylands Capital LLC now owns 55,775 shares of the medical instruments supplier’s stock valued at $3,545,000 after buying an additional 28,600 shares during the period. Institutional investors own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on HAE. Weiss Ratings cut Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday. Raymond James Financial cut Haemonetics from a “strong-buy” rating to an “outperform” rating and cut their price target for the company from $105.00 to $78.00 in a research note on Monday, August 11th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $62.00 price target (down from $85.00) on shares of Haemonetics in a research note on Friday, August 8th. Barrington Research reiterated an “outperform” rating and issued a $86.00 price target on shares of Haemonetics in a research note on Tuesday, October 21st. Finally, Mizuho cut their price target on Haemonetics from $90.00 to $70.00 and set an “outperform” rating for the company in a research note on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Haemonetics currently has an average rating of “Moderate Buy” and an average price target of $75.89.

Haemonetics Stock Down 0.2%

Shares of NYSE:HAE opened at $51.24 on Friday. The company has a fifty day moving average of $51.70 and a 200-day moving average of $62.43. The company has a market capitalization of $2.47 billion, a PE ratio of 15.67, a price-to-earnings-growth ratio of 0.95 and a beta of 0.37. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.04 and a current ratio of 1.72. Haemonetics Corporation has a 52-week low of $47.31 and a 52-week high of $94.99.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.09. The company had revenue of $321.39 million during the quarter, compared to the consensus estimate of $305.12 million. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The company’s revenue for the quarter was down 4.4% compared to the same quarter last year. During the same period in the prior year, the business earned $1.02 earnings per share. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. On average, equities analysts predict that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.